alternating between hope and deception. They are now disillusioned people. Each year brings a fresh crop of original systems, but chemists have found that they have only one chance in ten of purchasing a useful instrument since there is no way of telling the good from the bad on an exhibition stand.
remember a closed meeting held in Munich in 1978 between users and suppliers of laboratory products, which discussed the recurring problems of communication and cooperation. A top executive of a leading company, apparently exasperated by the usual mistrusting comments of the laboratory professionals, suddenly burst out 'The instrument companies have raised your profession to its present status. Without us you would still be playing with test tubes and bunsen burners down in the basements of your hospitals! You can't just go on ignoring what you owe to industry, treating us as junior partners, closing the door in our faces when we try to join your panels but at the same time asking for more and more free reagent samples and unlimited, unconditional instrument evaluation This is the gist of what he said, but he was most sincerely upset by the reaction of the laboratory professionals.
Meanwhile, was wondering why it was that an instrument evaluation in perhaps another country or by a different laboratory is never good enough for one's own purposes.
Instrument evaluation is a highly expensive activity in our laboratories even without such duplication. realized then that wasn't the only one to be unhappy with the situation, and that the communication gap was probably much larger than had suspected. No matter how much closer to each other the two sides may draw, cannot see the clinical chemist feeling indebted to industry for having contributed to the present status of his profession, nor will he expect any acknowledgement from industry. Cooperation in this context simply means that we try to add rather than cancel our respective efforts and expertise in an area of common interest. It is a means to self-realization, and has not a great deal to do with mutual support.
Indeed, we can only agree on means: our aims are different. Industry sells, we analyse. The common area is the instrument, but its definition is equivocal: for industry it is a product, to us it is a tool. And all too often it is prototype and a nuisance. Good communication must be sought at a still more basic level. Only when we have agreed proper definitions for such terms as 'sample throughput', 'throughput time', 'volume ratio', 'photometric accuracy', 'carry-over' etc., will those terms carry unequivocal information.
The role of industry as a leading force in the technological development of laboratories cannot be questioned. What can be questioned is the ultimate value of this development for which industry cannot be completely blameless. The truth is that we have no reason to be too proud of clinical chemica! practice today. But if industry insists on sharing credit for our successes, it must also be prepared to accept some responsibility for our failures. creating an unusually large market for small kits and socalled monotests, with the corresponding increase in price and quality control problems or, more likely just quality problems. They also perform 60% of all urine-screening, doubling the number of such strip tests per patient compared to France. Since these kits are twice as expensive, the Germanto-French ratio for this specific market is five to one, accounting for the difference in the size of population.
In such a situation control of the choice of tests, amount ordered, quality of result, and profit is entirely shared between the doctor and the manufacturer. The latter, being the more competent and better organized of both partners, is in a very strong position to advise his customer, particularly about methods and instruments. Until paying third-parties and/or patients become aware of the situation, willing to question the clinical justification of the request and sufficiently organized to do so, the trend cannot be expected to reverse. And the clinical chemist can have no influence in this case as he is completely outside the flowchart. There are cases, however where perhaps he could exert influence such as in the French hospitals where 32% vf all chemical tests are five electolytes (Na, K, CI, Ca, P). An extraordinary figure, which it is tempting to link with the undoubted success of Technicon's SMA in that country.
Whether they are created by economic or legal factors and maintained by profit groups, or clinically and scientifically justified, there are considerable quantitative and qualitative differences between the two major European countries in their approach to analyses. The Germans spend exactly twice as much as the French per inhabitant for analyses, doing 6 tests where the French do 3.8. The additional 2.2 are mainly glucose and enzymes (the Germans do twice as many glucose tests per inhabitant as the French). The costs of instruments and reagents, however, are about the same in both countries.
France is proportionately more automated than Germany. The Germans seem to ignore the use of calcium and potassium measurements. They do much more coagulation testing because they use prothrombin time as a hepatic parameter.
Because of legal hindrance the French do four times fewer RIA's etc. Most of these figures come from a recent work by Schoff 3 ], which casts a searching light on our profession. Obtaining similar data for other European countries would not only show the priorities for standardization, but would also teach us humility" there are also communication gaps within the profession. But there are common features also: screening, profiling, defensive medicine, and short term profit combine to generate a systematic over-production and underutilization of data. And industry shares the responsibility for this.
Let me complete this rather chaotic picture by insisting that the average quality of our results is still far from satisfactory and homogeneous, however tired we may be of harking back to the same old story. Automated instruments enable us to measure more specimens for more parameters but they are given undeserved credit for improving the quality of test results. Quality surveys constantly show that long term precision and accuracy of manual methods are just as good or even better. It is the quality of instruments and the value of calibrators, not the degree of mechanization, that have a decisive influence on the quality of results.
User's needs
Looking for the user in order to identify his needs, have been obliged to recognize a dramatic lack of coherence and efficiency in our profession. There is a danger that, having failed so far to present an organized front, clinical chemistry will be degraded into a number of marketing outlets and eventually retrieved by industry with the tacit approval of government, just like another pharmaceutical business. As everyone knows, drug inflation is considerably worse and less justified than test inflation and there is hardly any intermediary between the doctor and the manufacturer. Pharmaceutical companies are in a position where they can consciously disinform the physician, for example dissuading him from controlling his patients's drug levels, such as digoxin. Control of drug level would soon demonstrate the gross overdosage of these chemicals in the population and consequently compromise sales.
It is now a race against time. The twin origins of clinical chemistry make both for its wealth and its weakness. Each of us inevitably leans more either to the chemical or to the clinical side, so that each of us has his Achilles' heel. Industry, logically, has taken advantage of this duality from the very beginning, forcing oversimplified analytical concepts into the clinically-minded, and rudiments of diagnostics into the analytically minded. This is how such odd instruments as the Auto Analyzer were so widely accepted and how such nontests as the CEA (carcino-embryonic antigen) test manage to enter the market. We must not allow industry to simplify our investigational methods into a caricature and immobilize our profession to a sterile infantilism.
Our laboratories and, more specifically, our instruments, are components of a formidable venture called health care. Health care, Ralph Nader has said is a cost-plus, increasingly no-fault industry with no incentive to reduce costs. And he might have added 'or to increase efficiency'. Unlike other businesses, our laboratories are production systems with no feedback be it from the doctor, the patient, or anyone else. This endows us with a considerable responsibility if we believe that clinical chemistry can contribute to improving people's living. We are alone and free to decide what we are going to demand, to accept, and to refuse. am convinced that we could have avoided the dinosaurs.
am not sure that industry should have concerned itself with the diagnostic use of tests or even with analytical methods. Making appropriate analytical instruments could have been sufficient. But now that it has entered the clinical field, advising on the relative merits of tests, industry should involve itself much further with the problem; it should invest in training, learn about biological variation and statistics,clinical relevance, parametric testing etc., instead of simply laying out another advertisement each time a new test is discovered and trying to sell it like a new vitamin preparation. And this will require much closer and more systematic cooperation with the profession (the emerging European Committee for Clinical Laboratory Standards, ECCLS, may be the framework for such cooperation). As far as instruments are concerned we would like them to be rugged and safe. Material and reagent should be used at the ultramicro level. Measuring devices should be accurate and stable. Flexibility should result from modularity and miniaturization. Mechanical movements should be quick: much quicker than their manual counterparts. Instruments should stem from a systems analysis of every aspect of laboratory work from and including blood withdrawal to reporting. Every available analytical technique should be envisaged, not just visible absorption spectometry. And additionally all these facets may be automated why not?
